News

With the support of grants from the Alberta Livestock and Meat Agency and Genome Canada, Chronix is working in partnership with the University of Calgary to develop a

Sort Out IV, a randomised trial, was designed to test whether the Xience V stent is non-inferior to the Cypher stent. Reportedly, both drug-eluting stents performed better than

VaxDesign is the developer of the Modular IMmune In-vitro Construct (MIMIC) technology that melds immunology with engineering to find solutions to complex biological problems. MIMIC will be relevant

SBIO claims that SB939 is designed to be a best-in-class HDAC inhibitor, and has demonstrated the potential to bring additional therapeutic benefits due to its high potency, superior

The study also is also expected to investigate the pharmacokinetics of KAI-4169 and its effect on parathyroid hormone (PTH) and serum calcium levels. The data from Phase 1

The Perrigo product is a proton pump inhibitor and antacid indicated for the treatment of frequent heartburn. Perrigo has also provided prior notice of this filing to Schering-Plough

As per the extended agreement, Wyeth’s commercialisation efforts in the US is expected to continue through 31 December 2010, and may be extended at Progenics’ option to 31

OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition OctoPlus offers its clients drug delivery technologies for the development of

According to Progenika Biopharma, the diagnostic test rapidly diagnoses patients with complete and partial lipoprotein lipase deficiency (LPLD) and has been developed under an agreement with Amsterdam Molecular